Skip to main content

Table 1 Baseline characteristics of participants completing the study

From: Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels

 Participants (n = 56)
Sex
 Female/male9/47
Age (years)
 Mean (range)60.7 (46–73)
Smoking (Y/N)11/45
Blood pressure [mean ± SD]
 Systolic (mmHg)132.0 ± 16.32
 Diastolic (mmHg)80.0 ± 9.51
Physical examination [mean ± SD]
 Height (m)1.72 ± 0.07
 Weight (kg)96.18 ± 17.60
 BMI32.70 ± 5.23
Baseline blood tests [mean ± SD]
 HbA1c (mmol/mol)71.60 ± 22.99
 Sodium (mmol/L)139.28 ± 2.39
 Potassium (mmol/L)4.48 ± 0.39
 Creatinine (μmol/L)83.13 ± 20.66
 Urea (mmol/L)6.20 ± 2.41
 eGFR (mL/min/1.73 m2)80.70 ± 13.24
 Total cholesterol (mmol/L)3.79 ± 0.77
 LDL (mmol/L)1.89 ± 0.49
 HDL (mmol/L)1.08 ± 0.26
 Triglycerides (mmol/L)2.06 ± 2.01
 FT4 (pmol/L)15.10 ± 2.12
 TSH (mIU/L)2.00 ± 1.12
History of macrovascular disease32 (57%)
Microvascular complications
 Retinopathy23 (41%)
 Nephropathy9 (16%)
 Neuropathy15 (27%)
Concomitant medication and therapies
 Diabetes related
  Metformin48 (86%)
  Sulphonylurea15 (27%)
  Gliptin6 (11%)
  Glitazone5 (9%)
  GLP-1 analogues5 (9%)
  SGLT2-inhibitors0 (0%)
  Insulin27 (48%)
 Antihypertensives
  ACE inhibitor/ARB48 (86%)
  Calcium channel blocker13 (23%)
  Diuretic16 (29%)
  Beta-blockers26 (47%)
  Αlpha-blockers5 (9%)
 Lipid-lowering
  Statin52 (93%)
  Fibrate1 (2%)
  Ezetimibe7 (13%)
  1. ARB angiotensin receptor blocker, FT4 free thyroxine, GLP-1 glucagon like peptide 1, SGLT2 sodium-glucose transporter 2, TSH thyroid stimulating hormone